Back into focus: tumour-associated macrophages and their role in immune checkpoint inhibition

The onset of immune checkpoint inhibition in clinical oncology has shed light on new and promising treatment options for various types of cancer including melanoma (1,2), non-small cell lung cancer (NSCLC) (3,4), renal cell carcinoma (5) as well as kidney cancer (6) leading to unexpected high tumour responses and shifting the focus of current research attention on the host´s immune response.